[Skip to Navigation]
June 19, 2019

Use of Dupilumab in the Treatment of Papuloerythroderma of Ofuji

Author Affiliations
  • 1Department of Dermatology, Saitama Medical University, Saitama Medical Center, Saitama, Japan
JAMA Dermatol. 2019;155(8):979-980. doi:10.1001/jamadermatol.2019.0946

Papuloerythroderma of Ofuji (PEO) is a distinct clinical entity characterized by pruritic, erythroderma-like eruption comprising confluent papules sparing the skin folds (deck-chair sign).1,2 It occurs in elderly men and is often associated with blood eosinophilia and elevated serum immunoglobulin E (IgE) levels. Recent reports have suggested that T helper type 2 (TH2) cells could be important in the pathogenesis of PEO.3 Dupilumab is an interleukin (IL)-4 receptor α-antagonist that inhibits IL-4 and IL-13 signaling.4 This report describes 2 patients with PEO who were successfully treated with dupilumab.

Add or change institution